Clinical Trial: A randomized, controlled, open-label, multicenter phase II clinical study evaluating the safety and efficacy of bevacizumab combined with teniposide in the treatment of recurrent glioblastoma. (China)

China, Oct. 28 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A randomized, controlled, open-label, multicenter phase II clinical study evaluating the safety and efficacy of bevacizumab combined with teniposide in the treatment of recurrent glioblastoma.'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600135234

Registration Time: 2026/10/27

Type: Interventional study

Primary Sponsor: Tangdu Hospital of the Fourth Military Medical University of the People's Liberation Army of China

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=348940

Published by HT Digital Content Services with permission from Health Daily Digest...